Breast Cancer

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7